immunotherapy Archives - Page 2 of 3

Second-line treatment options in hepatocellular carcinoma

Donatella Marino MD, Clizia Zichi MD, Marco Audisio MD, Elisa Sperti MD, Massimo Di Maio MD

Article Type

Review

Published

10 Apr 2019

This review discusses the evidence on second-line options for hepatocellular carcinoma, focusing on the latest results that are currently refining the treatment scenario.

Immunotherapy in non-melanoma skin cancer: updates and new perspectives

Paolo Antonio Ascierto MD, Dirk Schadendorf MD, PhD

Article Type

Conference Report

Published

28 Mar 2019

This article provides background on NMSC and describes
the updates and new perspectives that were discussed during
the symposium ‘CSCC It Bridge’ held in Naples, Italy, 28–29
November 2018.

Agents to treat BRAF-mutant lung cancer

Jean G Bustamante Alvarez MD, MS, Gregory A Otterson MD

Article Type

Review

Published

13 Mar 2019

Cutaneous side effects of molecularly targeted therapies for the treatment of solid tumors

Daniel I G Cubero MD, PhD, Beatrice Martinez Zugaib Abdalla MD, Jean Schoueri, Fabio Iazetti Lopes, Karine Corcione Turke, Jose Guzman MD, Auro Del Giglio MD, PhD, Carlos D’Apparecida Santos Machado Filho MD, PhD, Vanessa Salzano MD, Dolores Gonzalez Fabra MD

Article Type

Review

Published

17 Jul 2018

This article reviews the cutaneous side effects of main molecularly targeted cancer therapies for solid tumors.

Regorafenib in hepatocellular carcinoma: latest evidence and clinical implications

Nicola Personeni MD, Tiziana Pressiani MD, Armando Santoro MD, Lorenza Rimassa MD

Article Type

Review

Published

27 Jun 2018

Over the past ten years, sorafenib has been the only systemic agent approved for first-line treatment of patients with unresectable hepatocellular carcinoma (HCC) and in a second-line setting, most investigational drugs have failed to provide better survival outcomes than placebo. However, in 2016, data from the RESORCE trial, a phase 3 study evaluating regorafenib in HCC patients who experience disease progression after first-line treatment with sorafenib, have shown a 2.8-month median survival benefit over placebo (10.6 versus 7.8 months).